Print this page
Radiation
-
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers Big Ten Cancer Research Consortium BTCRC-GI22-564
Protocol: 072401Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Small Intestine -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Protocol: 072403Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Pancreas -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Protocol: 081602Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined with Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men with Newly Diagnosed Metastatic Prostate Cancer. (Multi-center)
Protocol: 081707Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Prostate -
A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer.
Protocol: 081805Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Kidney -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*).
Protocol: 082101Applicable Disease Sites: Prostate
-
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE).
Protocol: 082104Principal Investigator:
-
Tina Mayer
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Other Female Genital
Other Male Genital
Urinary Bladder -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Protocol: 082304Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Prostate -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Kidney -
A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol: 082401Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
-
Ryan Stephenson
Applicable Disease Sites: Melanoma, Skin